Revolution Medicines, Inc.
Revolution Medicines, Inc. Q3 FY2025 earnings call
November 5, 2025 · fiscal period ended 2025-09
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2025-11-05
Management highlights
• Pipeline progress: Daraxonrasib in pancreatic cancer has FDA special designations, with clinical updates from Phase I monotherapy cohort showing strong antitumor activity. RASolute 302 near enrollment completion, RASolute 303 to initiate this year, RASolute 304 Phase III trial initiated. Zoldonrasib, elironrasib, RMC-5127 updates. Collaborations with Tango Therapeutics and Summit Therapeutics. • Financials: Ended Q3 2025 with $1.93B in cash and investments. R&D expenses increased due to clinical trials and manufacturing. G&A expenses increased. Projected full-year 2025 GAAP net loss between $1.03B and $1.09B. • Partnerships and advocacy: Expanded partnerships with advocacy community for patient-focused clinical protocols and access solutions.
Segment performance
No traditional product segment revenue contribution details provided in the transcript.
Guidance
• Reiterating 2025 financial guidance: Projected full year 2025 GAAP net loss to be between $1.03 billion and $1.09 billion, including noncash stock-based compensation expense between $115 million and $130 million.
Risks
• Risks related to clinical trial outcomes not meeting expectations, regulatory approval delays for pipeline assets, and challenges in commercializing products successfully.
Q&A highlights
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Q: How are you thinking about the impact of receiving the Commissioner's National Priority Voucher on daraxonrasib time lines and your plans?
A: Mark Goldsmith states they're proud of the voucher, which aims to accelerate review timelines and they'll support that.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | $-1.61 | $-1.42 | -13.4% | — |
| Revenue | — | $1.7M | — | — |
Transcript
November 5, 2025Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.